Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Apr;145(4):481-489.
doi: 10.1017/S0031182017002116. Epub 2017 Dec 7.

Chemotherapeutics of visceral leishmaniasis: present and future developments

Shyam Sundar  1 , Anup Singh  1
Affiliations
Review

Chemotherapeutics of visceral leishmaniasis: present and future developments

Shyam Sundar et al. Parasitology. 2018 Apr.

Abstract

Treatment of Visceral Leishmaniasis (VL), a neglected tropical disease, is very challenging with few treatment options. Long duration of treatment and drug toxicity further limit the target of achieving VL elimination. Chemotherapy remains the treatment of choice. Single dose of liposomal amphotericin B (LAmB) and multidrug therapy (LAmB + miltefosine, LAmB + paromomycin (PM), or miltefosine + PM) are recommended treatment regimen for treatment of VL in Indian sub-continent. Combination therapy of pentavalent antimonials (Sbv) and PM in East Africa and LAmB in the Mediterranean region/South America remains the treatment of choice. Various drugs having anti-leishmania properties are in preclinical phase and need further development. An effective treatment and secondary prophylaxis of HIV-VL co-infection should be developed to decrease treatment failure and drug resistance.

Keywords: Amphoterecin B; Kala-Azar; Miltefosine; Paromomycin; Visceral leishmaniasis.

PubMed Disclaimer

References

    1. Alvar J, Aparicio P, Aseffa A, Den Boer M, Canavate C, Dedet JP, Gradoni L, Ter Horst R, Lopez-Velez R, Moreno J. The relationship between leishmaniasis and AIDS: the second 10 years. Clinical Microbiology Reviews. 2008;21:334–59. - PMC - PubMed
    1. Alvar J, Canavate C, Gutierrez-Solar B, Jimenez M, Laguna F, Lopez-Velez R, Molina R, Moreno J. Leishmania and human immunodeficiency virus coinfection: the first 10 years. Clinical Microbiology Reviews. 1997;10:298–319. - PMC - PubMed
    1. Alvar J, Velez ID, Bern C, Herrero M, Desjeux P, Cano J, Jannin J, den Boer M. Leishmaniasis worldwide and global estimates of its incidence. PLoS One. 2012;7:e35671. - PMC - PubMed
    1. Badaro R. The use of recombinant gamma interferon associated with pentavalent antimony in therapy for visceral leishmaniasis. Memórias do Instituto Oswaldo Cruz. 1988;83(Suppl 1):376–7. - PubMed
    1. Badaro R, Falcoff E, Badaro FS, Carvalho EM, Pedral-Sampaio D, Barral A, Carvalho JS, Barral-Netto M, Brandely M, Silva L, et al. Treatment of visceral leishmaniasis with pentavalent antimony and interferon gamma. New England Journal of Medicine. 1990;322:16–21. - PubMed

Publication types

MeSH terms